CN104198408A - Detection kit for determining content of creatinine in serum by enzymic method - Google Patents
Detection kit for determining content of creatinine in serum by enzymic method Download PDFInfo
- Publication number
- CN104198408A CN104198408A CN201410401289.8A CN201410401289A CN104198408A CN 104198408 A CN104198408 A CN 104198408A CN 201410401289 A CN201410401289 A CN 201410401289A CN 104198408 A CN104198408 A CN 104198408A
- Authority
- CN
- China
- Prior art keywords
- reagent
- detection kit
- creatinine
- kit according
- absorbance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a detection kit for determining the content of creatinine in serum by an enzymic method. The detection kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 contains 3-10g/L of buffering solution with the pH value being 7.5-8.0, 0.2-0.5g/L of EDTA, 0.5-2g/L of N-ethyl-N-(2-hydroxyl-3-sulfopropyl) m-toluidine sodium salt, 1 per mill-5 per mill of a surface active agent, 0.2-1g/L of sarcosine oxidase, 1-5KU/L of ascorbate oxidase, 2-5KU/L of creatinase and 0.5-1g/L of a stabilizing agent; the reagent R2 contains 3-10g/L of buffering solution with the pH value being 7.5-8.0, 0.1-0.5g/L of 4-aminoantipyrine, 0.1-0.4g/L of potassium ferricyanide, 2-8g/L of creatininase amidohydrolase, 1-6KU/L of peroxidase and 0.5-2g/L of a preservative. The detection kit disclosed by the invention is excellent in stability, strong in interference resistance and high in clinical application value.
Description
Technical field
The present invention relates to the detection kit of a kind of enzymatic assays creatinine in serum (CRE) content.
Background technology
Creatinine (creatinine, Cre) be muscle at human body metabolism's product, every 20g muscle metabolism can produce 1mg creatinine.In blood, creatinine is from two kinds of exogenous and endogenouss, and exogenous creatinine is the meat food product after metabolism in vivo; Endogenous creatinine is the product of musculature metabolism in body.When meat food intake is stablized, the muscle metabolism of health does not have again large variation, and the generation of creatinine will be more constant.
It is the efficiency index of evaluation of renal glomerular filtration rate (GFR) that serum creatinine concentration is measured, when acute renal failure and chronic progressive external renal failure, the mensuration of serum creatinine contributes to the clinical judgment state of an illness, particularly paediatrics and renal transplant patient's the diagnosis course of disease judges observation of curative effect etc., the serum creatinine continuously result of monitoring has more clinical reference value but a test rating can is applied to clinical prerequisite is that measurement result must be accurately and reliably, moreover serum creatinine measured value is again to calculate the Mathematics Proof of GFR, only has its measurement result accurately with reproducible, the accurate calculating of guarantee GFR.
Creatinine method is measured in lab analysis at present capillary electrophoresis high performance liquid chromatography (HPLC) electrode method enzyme process and chemical assay (being alkaline picric acid method), and latter two method is more conventional in clinical testing.
Alkaline picric acid method is to use creatinine to react with alkaline picric acid to generate orange-yellow compound, i.e. Jaffe reaction, detects absorbance, absorbance and the linear ratio of creatinine content at wavelength 505～520nm place.But cholerythrin also has absorption peak at 500～520nm wavelength place, simultaneously, in sodium hydroxide solution, cholerythrin in serum can be converted into dehydrobilirubin, dehydrobilirubin can have more by force and absorb at wavelength 620nm, can weaken former absorption, this impact can be covered the normal colour developing of Jaffe reaction, finally causes creatinine testing result to occur deviation.The principle that has a kind of enzymic colorimetric is to using creatinine as substrate, through creatinine imido hydrolytic enzyme catalysis deamination, generate methyl hydantoins, ammonia and α-ketoglutaric acid and NADH generate glutamic acid in the effect of glutamte dehydrogenase, NAD and water, the absorbance rate of change of measuring NADH under 340nm wavelength, calculates its content.Although the method only need just can complete whole reaction by two steps, in sample, endogenous ammonia becomes main interference factors, and measurement result is had to impact.
Summary of the invention
Object of the present invention overcomes the defect that above-mentioned available reagent box exists, and the detection kit of a kind of enzymatic assays creatinine in serum (CRE) content is provided.Adopt enzyme process test kit of the present invention to detect the CRE content in serum, can reach easy and simple to handle, good stability, specificity is good, fast, measurement result object accurately and reliably.
The detection principle that the present invention measures CRE content is: adopt creatinine amidohydrolase hydrolytic enzyme hydrolysis creatinine to produce creatine, kreatinase hydrolysis creatine produces methyl amimoacetic acid, and methyl amimoacetic acid produces H under sarcosine oxidase effect
2o
2, and then the Trinder of coupling Catalyzed Synthesis By Peroxidase reaction colorimetric estimation, concrete steps are as follows:
The object of the invention is to be achieved through the following technical solutions:
The present invention relates to the detection kit that a kind of enzyme process detects creatinine in serum content, comprise reagent R1 and reagent R2; The damping fluid that described reagent R1 contains 3～10g/L pH=7.5～8.0,0.2～0.5g/L ethylenediamine tetraacetic acid (EDTA), 0.5～2g/L N-ethyl-N-(2-hydroxyl-3-sulfopropyl) meta-aminotoluene sodium salt, 1 ‰～5 ‰ (that is: accounting for the weight percent content of reagent R1 gross weight) surfactant, 0.2～1g/L sarcosine oxidase, 1～5KU/L ascorbic acid oxidase, 2～5KU/L kreatinase and 0.5～1g/L stabilizing agent; The damping fluid that described reagent R2 contains 3～10g/L pH=7.5～8.0,0.1～0.5g/L4-amino-antipyrine, 0.1～0.4g/L high-potassium ferricyanide, 2～8g/L Creatininase, 1～6KU/L peroxidase and 0.5～2g/L antiseptic.
Preferably, the damping fluid comprising in described reagent R1, R2 is selected from respectively trishydroxymethylaminomethane (TRIS), propane sulfonic acid (MOPS), 4-hydroxyethyl piperazine ethanesulfonic acid (HEPES) or BICN.
Preferably, described surfactant is polysorbas20, Tween 80 or triton x-100.Polysorbas20 more preferably.
Preferably, described stabilizing agent is polyvalent alcohol, bovine serum albumin(BSA) (BSA) or beta-schardinger dextrin-.
Preferably, described polyvalent alcohol comprises sweet mellow wine or glycerine.
Preferably, described antiseptic is polylysine, potassium sorbate or sodium acetate.
The invention still further relates to a kind of using method of aforesaid detection kit, reagent R1 adds after sample 37 ℃ to hatch 5 minutes, reads absorbance A
0, then add reagent R2, hatch 5 minutes, read absorbance A for 37 ℃
1, calculate absorbance rate of change Δ A=A
1-A
0; Compare with creatinine content and the absorbance relation curve of CRE standard items, obtain the creatinine content of sample.
Preferably, the volume ratio of described reagent R1 and reagent R2 is 3: 1.
Preferably, the predominant wavelength that described monitoring adopts is 546nm, and commplementary wave length is 700nm.
Compared with prior art, the present invention has following beneficial effect:
1. in R1 reagent of the present invention, add polyvalent alcohol, bovine serum albumin(BSA) (BSA) or beta-schardinger dextrin-as stabilizing agent, make the commercially available reagent stability of reagents ratio of the present invention better.
2. the present invention utilizes the feature of double reagent method in automatic analysis, in R1 reagent, has added kreatinase, and reaction can be eliminated the interference of endogenous creatine in sample.
3. the present invention has added ascorbic acid oxidase in order to eliminate the interference of ascorbic acid to oxidation reaction in R1 reagent.
4. the present invention has added high-potassium ferricyanide in order to eliminate bilirubinic interference in R2 reagent.
5, test shows, applies kit detection creatinine result precision of the present invention high, and precision is good, and kit good stability of the present invention, and the holding time is long.Kit of the present invention is applied widely, is convenient to promote the use of, and can be applicable to situation of all-level hospitals, sanitary precaution department and medical biotechnology R&D institution and measures creatinine in serum content.
Accompanying drawing explanation
By reading the detailed description of non-limiting example being done with reference to the following drawings, it is more obvious that other features, objects and advantages of the present invention will become:
Fig. 1 is the typical curve of CRE normative reference, and wherein X-axis represents the content of CRE, and Y-axis represents absorbance;
Fig. 2 is for adopting respectively the CRE reagent of reagent of the present invention and German Roche diagnostic products company limited, adopt Hitachi's automatic clinical chemistry analyzer to measure by each autoregressive parameter 50 parts of human serums (comprising normal and monstrosity) simultaneously, measured value is carried out to the schematic diagram of correlation analysis; Wherein X-axis represents is patients serum's result that reagent of the present invention is measured, and Y-axis represents is patients serum's result that German Roche diagnostic products company limited reagent is measured, coefficient R
2=0.999, regression equation is y=0.977x+4.168.
Embodiment
Below in conjunction with specific embodiment, the present invention is described in detail.Following examples will contribute to those skilled in the art further to understand the present invention, but not limit in any form the present invention.It should be pointed out that to those skilled in the art, without departing from the inventive concept of the premise, can also make some distortion and improvement.These all belong to protection scope of the present invention.Raw material in following examples is existing conventional raw material, can directly by businessman, buy acquisition.In following examples of the present invention, there is no the operation of special instruction, all can adopt existing routine techniques means.
embodiment 1
Mensuration kit is composed as follows:
1. reagent R1 is:
2. reagent R2 is:
Various compositions can add under room temperature successively, or add simultaneously, or packing preparation immediately again before detecting separately respectively.
3. reagent detection ratio is 3: 1
The CRE detection kit that the present embodiment is described, is applicable to various types of full automatic biochemical apparatus, and Hitachi's 7170 full automatic biochemical apparatus of take are example, and it operates as table 1.Analytical approach: Two point end assay, the consumption of reagent R1, R2 is respectively 240ul and 80ul, sample size 5ul; 240ul reagent R1 adds 5ul sample to hatch 5min in 37 ℃, reads absorbance A
0, add 80ul R2, hatch 5min, read absorbance A for 37 ℃
1, calculate Δ A=A
1-A
0; Detection predominant wavelength is 546nm, and commplementary wave length is 700nm.
Adopt this reagent and said determination method, the curve (as shown in Figure 1) of the CRE standard items (C.f.a.s. of Roche company) that employing Hitachi 7170 Biochemical Analyzers record, wherein X-axis represents CRE content (umol/L); Y-axis represents absorbance.
Table 1
embodiment 2
Mensuration kit is composed as follows:
1. reagent R1 is:
2. reagent R2 is:
Various compositions can add under room temperature successively, or add simultaneously, or packing preparation immediately again before detecting separately respectively.
3. reagent detection ratio is 3: 1
The CRE detection kit that the present embodiment is described, is applicable to various types of full automatic biochemical apparatus, and Hitachi's 7170 full automatic biochemical apparatus of take are example, and it operates as table 1.Analytical approach: Two point end assay, the consumption of reagent R1, R2 is respectively 240ul and 80ul, sample size 5ul; 240ul reagent R1 adds 5ul sample to hatch 5min in 37 ℃, reads absorbance A
0, add 80ul R2, hatch 5min, read absorbance A for 37 ℃
1, calculate Δ A=A
1-A
0; Detection predominant wavelength is 546nm, and commplementary wave length is 700nm.
embodiment 3
Mensuration kit is composed as follows:
1. reagent R1 is:
2. reagent R2 is:
Various compositions can add under room temperature successively, or add simultaneously, or packing preparation immediately again before detecting separately respectively.
3. reagent detection ratio is 3: 1
The CRE detection kit that the present embodiment is described, is applicable to various types of full automatic biochemical apparatus, and Hitachi's 7170 full automatic biochemical apparatus of take are example, and it operates as table 1.Analytical approach: Two point end assay, the consumption of reagent R1, R2 is respectively 240ul and 80ul, sample size 5ul; 240ul reagent R1 adds 5ul sample to hatch 5min in 37 ℃, reads absorbance A
0, add 80ul R2, hatch 5min, read absorbance A for 37 ℃
1, calculate Δ A=A
1-A
0; Detection predominant wavelength is 546nm, and commplementary wave length is 700nm.
comparative example 1
The mensuration kit of this comparative example is composed as follows:
1. reagent R1 is:
2. reagent R2 is:
Various compositions can add under room temperature successively, or add simultaneously, or packing preparation immediately again before detecting separately respectively.
comparative example 2
The mensuration kit of this comparative example is composed as follows:
1. reagent R1 is:
2. reagent R2 is:
Various compositions can add under room temperature successively, or add simultaneously, or packing preparation immediately again before detecting separately respectively.
comparative example 3
The mensuration kit of this comparative example is composed as follows:
1. reagent R1 is:
2. reagent R2 is:
Various compositions can add under room temperature successively, or add simultaneously, or packing preparation immediately again before detecting separately respectively.
comparative example 4
The mensuration kit of this comparative example is composed as follows:
1. reagent R1 is:
2. reagent R2 is:
Various compositions can add under room temperature successively, or add simultaneously, or packing preparation immediately again before detecting separately respectively.
the correlation test of embodiment 4, detection reagent
Use the CRE reagent of this law invention reagent (specifically filling a prescription with embodiment 1) and contrast agents Germany Roche diagnostic products company limited, adopt automatic 7170 automatic clinical chemistry analyzers to measure by each autoregressive parameter 50 parts of human serums (comprising normal and monstrosity) simultaneously, measured value is carried out to correlation analysis.According to above-mentioned " table 1 " in parameter measure measurement result and see Fig. 2, X, Y-axis is measured value (the content umol/L of CRE),
Result by Fig. 2 finds out, the relevant of two kinds of reagent is R
2=0.999, regression equation is y=0.977x+4.168.It is good that result shows that this reagent and import reagent are measured patients serum's correlativity, has good specificity and accuracy.
In addition, above experiment is that 7170 full automatic biochemical apparatus that adopt Hitachi, Ltd to manufacture carry out, but reagent of the present invention is not limited to above-mentioned instrument, is also applicable to other full-automatic or semi-automatic biochemical analyzers.
embodiment 5, replica test
This experiment purpose is to detect reagent repeatability.
Adopt embodiment 1 reagent, contrast agents (Jiaxing is rich safe biological), standard items, blank solution (being generally normal saline solution and Purified Water), normal human serum sample.
Machine: Hitachi's 7170 automatic biochemistry analyzers.
Operation steps: test 10 times serum sample, calculate average and SD numerical value, try to achieve CV numerical value.
Result is resolved: according to detecting data, calculate CV numerical value, CV numerical value more approaches 0, represents that repeatability is better.
Table 2 result shows, the coefficient of variation CV=0.89% of reagent detection creatinine of the present invention, and rich safe biological reagent detects the coefficient of variation CV=2.29% of creatinine, and the CV value that reagent of the present invention detects reagent is less than rich safe biological reagent, shows that reagent of the present invention is reproducible.
The replica test of embodiment 2,3 reagent is the same, and testing result, substantially with embodiment 1, shows that reagent of the present invention has good repeatability.
Table 2
| Sequence number | Reagent of the present invention | Rich safe biological reagent |
| 1 | 120.39 | 120.7 |
| 2 | 120.39 | 123.46 |
| 3 | 117.15 | 122.38 |
| 4 | 120.86 | 121.84 |
| 5 | 119.68 | 121.3 |
| 6 | 119.69 | 124 |
| 7 | 118.77 | 125.54 |
| 8 | 120.39 | 121.62 |
| 9 | 119.85 | 115.08 |
| 10 | 119.31 | 123.08 |
| Mean value | 119.65 | 121.90 |
| SD | 1 | 2.79 |
| CV％ | 0.89％ | 2.29％ |
embodiment 6, accuracy experiment
This experiment purpose is to detect reagent accuracy.
Operation steps: test respectively the high and low value quality controlled serum of Roche 3 times, calculate average and with the relative deviation of quality-control product target value.
Result is resolved: according to detecting data, calculate relative deviation, the absolute value of deviation is less, represents that accuracy is higher.
The demonstration of table 3 result, reagent of the present invention (embodiment 1) is measured the high and low value determination of serum of the multinomial biochemistry quality control of Roche mean value and is respectively 86.43umol/L, 353.63umol/L, is respectively 0.26% and 0.75% with the relative deviation of target value; Rich safe biological reagent is measured mean value and is respectively 92.32umol/L, 373.42umol/L, is respectively 7.10% and 6.39% with the relative deviation of target value.The accuracy that shows reagent of the present invention is high.
The accuracy test of embodiment 2,3 reagent is the same, and testing result, substantially with embodiment 1, shows that reagent of the present invention has good accuracy.
Table 3
embodiment 7, stability experiment
This experiment purpose is to detect reagent stability.
Operation steps: utilize Hitachi's 7170 automatic clinical chemistry analyzers, detect the blank absorbency of reagent described in the embodiment 1, comparative example 1,2 of different time under 2～8 ℃ of environment and other producers (rich safe biological) reagent, relatively its absorbance changes.Adopt pure water to detect on Biochemical Analyzer as dummy, record detects sample absorbance as requested.As sample blank absorbency is being tested under predominant wavelength, the absorbance of (end of this project parameters is a bit) when register instrument test reading finishes.
Table 4 result shows, compares with comparative example 1 reagent that does not add stabilizing agent, and the blank absorbency of reagent of the present invention in half a year changes much smaller than comparative example 1 reagent.Compare with adding comparative example 2 reagent of stabilizing agent glycerine, the blank absorbency variation of reagent of the present invention in half a year is significantly less than comparative example 2 reagent, shows that the stabilizing agent adding in reagent of the present invention is than the better effects if of glycerine.Compare with rich safe biological reagent, reagent interior blank absorbency half a year of the present invention changes the blank absorbency that is significantly less than rich safe biological reagent, shows that reagent stability of the present invention is better than rich safe biological reagent.In sum, the stabilizing agent effect adding in reagent of the present invention is remarkable, and reagent stability is good.
The stability test of embodiment 2,3 reagent is the same, and testing result, substantially with embodiment 1, shows that reagent of the present invention has good stability.
Table 4
| Time (d) | Reagent of the present invention | Comparative example 1 reagent | Comparative example 2 reagent | Rich safe biological reagent |
| 0 | 0.058 | 0.049 | 0.043 | 0.046 |
| 1 | 0.059 | 0.052 | 0.045 | 0.048 |
| 7 | 0.057 | 0.043 | 0.050 | 0.051 |
| 14 | 0.061 | 0.079 | 0.062 | 0.068 |
| 30 | 0.063 | 0.106 | 0.069 | 0.073 |
| 60 | 0.064 | 0.152 | 0.075 | 0.085 |
| 90 | 0.066 | 0.217 | 0.087 | 0.093 |
| 180 | 0.069 | 0.391 | 0.128 | 0.132 |
embodiment 8, interfering material impact
Respectively by the interfering material solution of variable concentrations gradient (ascorbic acid (VC), cholerythrin), joining concentration is in 352 μ mol/L CRE calibration object solution, add the sample of ascorbic acid to use respectively embodiment 1 reagent and comparative example 3 reagent replication 3 times, average; Add bilirubinic sample to use respectively embodiment 1 reagent and comparative example 4 reagent replication 3 times, average.With the distilled water comparison that adds same volume, to observe and to add interfering material and the relative error that adds CRE measured value after distilled water, relative error is no more than ± and 10% to be considered as result interference-free.Table 5 result shows: reagent of the present invention is measured the result of the sample that adds variable concentrations ascorbic acid and added the relative error of the sample measurement result of same volume distilled water to be no more than 2%, can think that the testing result of this assay method is substantially interference-free when ascorbic acid concentrations is less than 1000mg/dl.And comparative example 3 does not add the measurement result of ascorbic acid oxidase reagent to show, its with add the relative error of the measurement result after distilled water all over 10%, measurement result is unstable, a little less than anti-VC interference performance.Show to add ascorbic acid oxidase effect remarkable in reagent.Table 6 result shows: reagent of the present invention is measured and added the result of the bilirubinic sample of variable concentrations and add the relative error of the sample measurement result of same volume distilled water to be no more than 2%, can think that the testing result of this assay method is substantially interference-free when bilirubin concentration is less than 100mg/L.And comparative example 4 does not add the measurement result of high-potassium ferricyanide reagent to show, its with add the relative error of the measurement result after distilled water all over 10%, measurement result is unstable, a little less than anti-cholerythrin interference performance.Show to add high-potassium ferricyanide effect remarkable in reagent.
Table 5
Table 6
Above specific embodiments of the invention are described.It will be appreciated that, the present invention is not limited to above-mentioned specific implementations, and those skilled in the art can make various distortion or modification within the scope of the claims, and this does not affect flesh and blood of the present invention.
Claims (10)
1. a detection kit for enzymatic assays creatinine in serum content, is characterized in that, comprises reagent R1 and reagent R2; The damping fluid that described reagent R1 contains 3～10g/L pH=7.5～8.0,0.2～0.5g/L EDTA, 0.5～2g/L N-ethyl-N-(2-hydroxyl-3-sulfopropyl) meta-aminotoluene sodium salt, 1 ‰～5 ‰ surfactant, 0.2～1g/L sarcosine oxidase, 1～5KU/L ascorbic acid oxidase, 2～5KU/L kreatinase and 0.5～1g/L stabilizing agent; The damping fluid that described reagent R2 contains 3～10g/L pH=7.5～8.0,0.1～0.5g/L4-amino-antipyrine, 0.1～0.4g/L high-potassium ferricyanide, 2～8g/L Creatininase, 1～6KU/L peroxidase and 0.5～2g/L antiseptic.
2. detection kit according to claim 1, is characterized in that, the damping fluid comprising in described reagent R1, R2 is selected from respectively TRIS, MOPS, HEPES or BICN.
3. detection kit according to claim 2, is characterized in that, the damping fluid comprising in described reagent R1, R2 is MOPS.
4. detection kit according to claim 1, is characterized in that, described surfactant is polysorbas20, Tween 80 or triton x-100.
5. detection kit according to claim 1, is characterized in that, described stabilizing agent is polyvalent alcohol, BSA or beta-schardinger dextrin-.
6. detection kit according to claim 5, is characterized in that, described polyvalent alcohol comprises sweet mellow wine or glycerine.
7. detection kit according to claim 1, is characterized in that, described antiseptic is polylysine, potassium sorbate or sodium acetate.
8. according to a using method for the detection kit described in any one in claim 1～7, it is characterized in that, reagent R1 adds after sample 37 ℃ to hatch 5 minutes, reads absorbance A
0, then add reagent R2, hatch 5 minutes, read absorbance A for 37 ℃
1, calculate absorbance rate of change Δ A=A
1-A
0; Compare with creatinine content and the absorbance relation curve of CRE standard items, obtain the creatinine content of sample.
9. the using method of detection kit according to claim 8, is characterized in that, the volume ratio of described reagent R1 and reagent R2 is 3: 1.
10. the using method of detection kit according to claim 8, is characterized in that, the predominant wavelength that described monitoring adopts is 546nm, and commplementary wave length is 700nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410401289.8A CN104198408A (en) | 2014-08-14 | 2014-08-14 | Detection kit for determining content of creatinine in serum by enzymic method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410401289.8A CN104198408A (en) | 2014-08-14 | 2014-08-14 | Detection kit for determining content of creatinine in serum by enzymic method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104198408A true CN104198408A (en) | 2014-12-10 |
Family
ID=52083733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410401289.8A Pending CN104198408A (en) | 2014-08-14 | 2014-08-14 | Detection kit for determining content of creatinine in serum by enzymic method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104198408A (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104568926A (en) * | 2015-01-20 | 2015-04-29 | 中国科学院长春应用化学研究所 | Creatinine detection method |
| CN105388146A (en) * | 2015-10-20 | 2016-03-09 | 北京中生金域诊断技术股份有限公司 | Kit for simultaneously detecting sodium, creatinine and microalbumin in urine |
| CN106198509A (en) * | 2016-06-15 | 2016-12-07 | 四川迈克生物科技股份有限公司 | For measuring test kit and the method for creatinine |
| CN106383237A (en) * | 2016-08-19 | 2017-02-08 | 基蛋生物科技股份有限公司 | A dry-sheet type serum creatinine detection reagent strip and a preparing method thereof |
| CN106556595A (en) * | 2015-09-30 | 2017-04-05 | 山东博科生物产业有限公司 | A kind of Picric kinetic method detection kit of strong antijamming capability |
| CN106645758A (en) * | 2017-01-03 | 2017-05-10 | 长沙中生众捷生物技术有限公司 | Detection reagent and test strip for creatinine |
| CN107505470A (en) * | 2017-08-10 | 2017-12-22 | 威特曼生物科技（南京）有限公司 | Stable creatinine detection reagent box and its application method |
| CN109406798A (en) * | 2018-10-29 | 2019-03-01 | 美康生物科技股份有限公司 | Creatinine enzyme process detection kit |
| CN109724933A (en) * | 2018-12-30 | 2019-05-07 | 山东博科生物产业有限公司 | A kind of reproducible aspartate amino transferase detection kit |
| CN111989402A (en) * | 2017-12-21 | 2020-11-24 | 美昂医疗解决方案两合公司 | Creatinine deiminase and use thereof |
| CN112067827A (en) * | 2020-11-16 | 2020-12-11 | 天津德祥生物技术有限公司 | Antibody diluent and blood type test card comprising same |
| CN112522364A (en) * | 2020-08-15 | 2021-03-19 | 中山标佳生物科技有限公司 | Uric acid kit for quickly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum |
| CN113418916A (en) * | 2021-07-02 | 2021-09-21 | 安徽惠邦生物工程有限公司 | Creatinine quantitative rapid detection test strip and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281000B1 (en) * | 1987-02-27 | 1991-10-16 | Konica Corporation | Multi-layer analytical element for creatinine analysis |
| US20040072277A1 (en) * | 2000-08-11 | 2004-04-15 | Bernhard Schaffar | Creatinine sensor calibration |
| CN1912594A (en) * | 2006-08-10 | 2007-02-14 | 福建省洪诚生物药业有限公司 | Chemiluminescence investigating method of creatinine in serum |
| CN101169420A (en) * | 2006-10-24 | 2008-04-30 | 苏州艾杰生物科技有限公司 | Creatine diagnosis reagent kit and creatine concentration determination method |
| CN101175999A (en) * | 2005-05-17 | 2008-05-07 | 雷迪奥米特医学公司 | Enzyme sensor including a water-containing spacer layer |
| CN102023158A (en) * | 2010-10-19 | 2011-04-20 | 李立和 | Method for enzymatically determining creatinine in serum by two steps |
| CN102253041A (en) * | 2011-06-20 | 2011-11-23 | 董理 | Creatinine detection kit |
| CN102721684A (en) * | 2012-05-24 | 2012-10-10 | 宁波美康生物科技股份有限公司 | Two-step enzyme measuring method and measuring reagent for creatinine in blood serum |
-
2014
- 2014-08-14 CN CN201410401289.8A patent/CN104198408A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281000B1 (en) * | 1987-02-27 | 1991-10-16 | Konica Corporation | Multi-layer analytical element for creatinine analysis |
| US20040072277A1 (en) * | 2000-08-11 | 2004-04-15 | Bernhard Schaffar | Creatinine sensor calibration |
| CN101175999A (en) * | 2005-05-17 | 2008-05-07 | 雷迪奥米特医学公司 | Enzyme sensor including a water-containing spacer layer |
| CN1912594A (en) * | 2006-08-10 | 2007-02-14 | 福建省洪诚生物药业有限公司 | Chemiluminescence investigating method of creatinine in serum |
| CN101169420A (en) * | 2006-10-24 | 2008-04-30 | 苏州艾杰生物科技有限公司 | Creatine diagnosis reagent kit and creatine concentration determination method |
| CN102023158A (en) * | 2010-10-19 | 2011-04-20 | 李立和 | Method for enzymatically determining creatinine in serum by two steps |
| CN102253041A (en) * | 2011-06-20 | 2011-11-23 | 董理 | Creatinine detection kit |
| CN102721684A (en) * | 2012-05-24 | 2012-10-10 | 宁波美康生物科技股份有限公司 | Two-step enzyme measuring method and measuring reagent for creatinine in blood serum |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104568926B (en) * | 2015-01-20 | 2017-05-17 | 中国科学院长春应用化学研究所 | Creatinine detection method |
| CN104568926A (en) * | 2015-01-20 | 2015-04-29 | 中国科学院长春应用化学研究所 | Creatinine detection method |
| CN106556595B (en) * | 2015-09-30 | 2019-04-30 | 山东博科生物产业有限公司 | A kind of Picric kinetic method detection kit of strong antijamming capability |
| CN106556595A (en) * | 2015-09-30 | 2017-04-05 | 山东博科生物产业有限公司 | A kind of Picric kinetic method detection kit of strong antijamming capability |
| CN105388146A (en) * | 2015-10-20 | 2016-03-09 | 北京中生金域诊断技术股份有限公司 | Kit for simultaneously detecting sodium, creatinine and microalbumin in urine |
| CN106198509B (en) * | 2016-06-15 | 2018-08-31 | 迈克生物股份有限公司 | Kit and method for measuring creatinine |
| CN106198509A (en) * | 2016-06-15 | 2016-12-07 | 四川迈克生物科技股份有限公司 | For measuring test kit and the method for creatinine |
| CN106383237A (en) * | 2016-08-19 | 2017-02-08 | 基蛋生物科技股份有限公司 | A dry-sheet type serum creatinine detection reagent strip and a preparing method thereof |
| CN106645758A (en) * | 2017-01-03 | 2017-05-10 | 长沙中生众捷生物技术有限公司 | Detection reagent and test strip for creatinine |
| CN107505470A (en) * | 2017-08-10 | 2017-12-22 | 威特曼生物科技（南京）有限公司 | Stable creatinine detection reagent box and its application method |
| CN111989402A (en) * | 2017-12-21 | 2020-11-24 | 美昂医疗解决方案两合公司 | Creatinine deiminase and use thereof |
| CN109406798A (en) * | 2018-10-29 | 2019-03-01 | 美康生物科技股份有限公司 | Creatinine enzyme process detection kit |
| CN109724933A (en) * | 2018-12-30 | 2019-05-07 | 山东博科生物产业有限公司 | A kind of reproducible aspartate amino transferase detection kit |
| CN112522364A (en) * | 2020-08-15 | 2021-03-19 | 中山标佳生物科技有限公司 | Uric acid kit for quickly and simply eliminating interference of calcium dobesilate and etamsylate medicines in serum |
| CN112522364B (en) * | 2020-08-15 | 2023-09-08 | 中山标佳生物科技有限公司 | Uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum |
| CN112067827A (en) * | 2020-11-16 | 2020-12-11 | 天津德祥生物技术有限公司 | Antibody diluent and blood type test card comprising same |
| CN113418916A (en) * | 2021-07-02 | 2021-09-21 | 安徽惠邦生物工程有限公司 | Creatinine quantitative rapid detection test strip and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104198408A (en) | Detection kit for determining content of creatinine in serum by enzymic method | |
| CN104198473B (en) | A kind of uric acid detection kit of stabilization | |
| CN102721684B (en) | Two-step enzyme measuring method and measuring reagent for creatinine in blood serum | |
| CN104198407A (en) | Detection kit for detecting content of beta-hydroxybutyrate in serum by adopting stable enzymatic method | |
| CN102023158A (en) | Method for enzymatically determining creatinine in serum by two steps | |
| NO300853B1 (en) | Assay methods, reagent composition and use thereof in glucose determination | |
| CN102650591A (en) | Kit for determining glycated serum protein | |
| CN104483487A (en) | Kit for detecting 1, 5-anhydro-D-ghlcitol in human blood | |
| CN101226198A (en) | Enzymatical detection method of saccharify blood albumen as well as liquid stabilising agent | |
| CN103048282B (en) | Detection method of bilirubin and detection kit | |
| CN107505273A (en) | Serum tolal bile acid assay kit and its application method | |
| CN104714040B (en) | Glucose in serum oxidase double reagent assay method | |
| CN104198421A (en) | Detection kit for measuring content of urea without interference of endogenous ammonia in serum | |
| CN107505470A (en) | Stable creatinine detection reagent box and its application method | |
| CN111944872A (en) | Reagent combination, reagent or kit for measuring creatinine content | |
| CN109988816A (en) | A kind of adenosine deaminase assay kit | |
| CN107153044A (en) | The homocysteine kit and its detection method of a kind of modified form | |
| CN103725749A (en) | Method for measuring 1,5-anhydroglucitol by oxidase | |
| CN102747133B (en) | Adenosine deaminase (ADA) detection reagent kit and preparation method thereof | |
| CN107254508B (en) | H2O2Kit for detecting sialic acid by coupled indicator system | |
| CN103837487A (en) | Uric acid detection method and detection kit | |
| CN110849870A (en) | Detection reagent for N-acetyl- β -D-glucosaminidase | |
| CN103602718A (en) | Method for testing triglyceride in serum by using glycerol dehydrogenase | |
| CN102901711A (en) | Sarcosine oxidase method for quantitatively detecting sarcosine and detection kit | |
| CN105445469B (en) | A kind of detection kit of ischemia modified albumin IMA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141210 |